BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20685321)

  • 1. Mitochondrial dysfunction in CD4+ lymphocytes from stavudine-treated HIV patients.
    Einsiedel L; Cherry CL; Sheeran FL; Friedhuber A; Wesselingh SL; Pepe S
    Mitochondrion; 2010 Aug; 10(5):534-9. PubMed ID: 20685321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients.
    Ciccosanti F; Corazzari M; Soldani F; Matarrese P; Pagliarini V; Iadevaia V; Tinari A; Zaccarelli M; Perfettini JL; Malorni W; Kroemer G; Antinori A; Fimia GM; Piacentini M
    Antivir Ther; 2010; 15(3):377-90. PubMed ID: 20516557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
    Rosso R; Nasi M; Di Biagio A; Repetto E; Dentone C; Pinti M; Nemes E; Ferraresi R; Mussini C; Esposito R; Viscoli C; Cossarizza A
    Pediatr Infect Dis J; 2008 Jan; 27(1):17-21. PubMed ID: 18162932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy.
    Haugaard SB; Andersen O; Pedersen SB; Dela F; Richelsen B; Nielsen JO; Madsbad S; Iversen J
    J Med Virol; 2005 Sep; 77(1):29-38. PubMed ID: 16032748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
    Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
    J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy.
    Cossarizza A; Riva A; Pinti M; Ammannato S; Fedeli P; Mussini C; Esposito R; Galli M
    Antivir Ther; 2003 Aug; 8(4):315-21. PubMed ID: 14518701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial effects of antiretroviral therapies in asymptomatic patients.
    López S; Miró O; Martínez E; Pedrol E; Rodríguez-Santiago B; Milinkovic A; Soler A; García-Viejo MA; Nunes V; Casademont J; Gatell JM; Cardellach F
    Antivir Ther; 2004 Feb; 9(1):47-55. PubMed ID: 15040536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy.
    Miró O; López S; Pedrol E; Rodríguez-Santiago B; Martínez E; Soler A; Milinkovic A; Casademont J; Nunes V; Gatell JM; Cardellach F
    Antivir Ther; 2003 Aug; 8(4):333-8. PubMed ID: 14526764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy.
    Casula M; Weverling GJ; Wit FW; Timmermans EC; Stek M; Lange JM; Reiss P
    J Infect Dis; 2005 Nov; 192(10):1794-800. PubMed ID: 16235179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.
    Sternfeld T; Schmid M; Tischleder A; Mudra S; Schlamp A; Kost BP; Gruber R; Youle M; Bogner JR; Goebel FD
    Antivir Ther; 2007; 12(5):769-78. PubMed ID: 17713160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial toxicity in HIV type-1-exposed pregnancies in the era of highly active antiretroviral therapy.
    Gingelmaier A; Grubert TA; Kost BP; Setzer B; Lebrecht D; Mylonas I; Mueller-Hoecker J; Jeschke U; Hiedl S; Friese K; Walker UA
    Antivir Ther; 2009; 14(3):331-8. PubMed ID: 19474467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.
    Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D
    J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial assessment in asymptomatic HIV-infected paediatric patients on HAART.
    Morén C; Noguera-Julian A; Rovira N; Garrabou G; Nicolàs M; Cardellach F; Martínez E; Sánchez E; Miró O; Fortuny C
    Antivir Ther; 2011; 16(5):719-24. PubMed ID: 21817193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.
    Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Solinas P; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):375-83. PubMed ID: 16584508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.
    Pace CS; Martin AM; Hammond EL; Mamotte CD; Nolan DA; Mallal SA
    Antivir Ther; 2003 Aug; 8(4):323-31. PubMed ID: 14518702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
    Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
    Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
    Côté HC; Magil AB; Harris M; Scarth BJ; Gadawski I; Wang N; Yu E; Yip B; Zalunardo N; Werb R; Hogg R; Harrigan PR; Montaner JS
    Antivir Ther; 2006; 11(1):79-86. PubMed ID: 16518963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
    Nolan D; Hammond E; James I; McKinnon E; Mallal S
    Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.